In this 12-week Phase IIa study, ISM001-055 met its primary endpoint of safety and tolerability across all dose levels. (IMAGE)

InSilico Medicine

In this 12-week Phase IIa study, ISM001-055 met its primary endpoint of safety and tolerability across all dose levels.

Caption

Positive results were also reported for the secondary efficacy endpoint, wherein a dose-dependent FVC improvement was observed. Patients receiving 60mg QD of ISM001-055 demonstrated the largest improvement in FVC.

Credit

Insilico Medicine

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.